Skip to main content

Table 7 Correlations of methylation levels of the promoter region of hTERT gene with baseline characteristics of patients in the recurrence and non-recurrence groups

From: The correlations between DNA methylation and polymorphisms in the promoter region of the human telomerase reverse transcriptase (hTERT) gene with postoperative recurrence in patients with thyroid carcinoma (TC)

Characteristic Non-recurrence group Recurrence group
  Hypomethylation (%) Hypermethylation (%) P Hypomethylation (%) (n = 22) Hypomethylation (%) (n = 53) P
Tumor size
 <20 mm 112 (70.0) 45 (58.4) 0.078 12 (54.5) 19 (35.8)  
 ≥20 mm 48 (30.0) 32 (41.6)   10 (45.5) 34 (64.2) 0.134
Multicentricity
 Yes 102 (63.8) 41 (53.2) 0.122 9 (40.9) 27 (50.9)  
 No 58 (36.3) 36 (46.8)   13 (59.1) 26 (49.1) 0.428
Extrathyroidal invasion
 Yes 57 (35.6) 31 (40.3) 0.489 8 (36.4) 25 (47.2) 0.391
 No 103 (64.4) 46 (59.7)   14 (63.6) 28 (52.8)  
Lymph node metastasis
 Yes 29 (18.1) 15 (19.5) 0.802 7 (31.8) 41 (77.4) <0.001
 No 131 (81.9) 62 (80.5)   15 (68.2) 12 (22.6)  
Pathological type
 Papillary thyroid carcinoma 147 (91.9) 73 (94.8) 0.707 12 (54.5) 25 (47.2)  
 Follicular thyroid carcinoma 7 (4.4) 3 (3.9)   2 (9.1) 5 (9.4)  
 Medullary thyroid carcinoma 4 (2.5) 1 (1.3)   2 (9.1) 8 (15.1)  
 Undifferentiated carcinoma 2 (1.3) 0 (0.0)   6 (27.3) 15 (28.3) 0.897
Tumor stage
 I + II 135 (84.4) 64 (83.1) 0.805 14 (63.6) 16 (30.2)  
 III + IV 25 (15.6) 13 (16.9)   8 (36.4) 37 (69.8) 0.007
  1. hTERT human telomerase reverse transcriptase